Status:
COMPLETED
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Breast Cancer
Metastatic Breast Cancer
Eligibility:
FEMALE
45-130 years
Phase:
PHASE2
Brief Summary
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
Eligibility Criteria
Inclusion
- Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.
- Requiring hormonal treatment.
- Postmenopausal women (woman who has stopped having menstrual periods)
Exclusion
- Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.
- Treatment with more than one previous regimen of endocrine therapy for advanced BC.
- An existing condition that prevents compliance.
Key Trial Info
Start Date :
May 30 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 13 2019
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00313170
Start Date
May 30 2006
End Date
March 13 2019
Last Update
January 6 2020
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Brussels, Belgium, 1000
2
Research Site
Leuven, Belgium, 3000
3
Research Site
Roeselare, Belgium, 8800
4
Research Site
Wilrijk, Belgium, 2610